#ES­MO22: At five-year mark, Lyn­parza kept more pa­tients alive than Avastin but missed over­all OS sig­nif­i­cance

PARIS — As­traZeneca and Mer­ck ar­rived at ES­MO with long-term da­ta on their block­buster can­cer drug and Eu­ro­pean con­fab sta­ple Lyn­parza, which ush­ered in the PARP in­hibitor mar­ket in De­cem­ber 2014.

The datasets this time around were a mixed bag — the Big Phar­ma part­ners de­tailed five-year fol­low-up re­sults to the PAO­LA-1 Phase III and sev­en-year analy­sis of the SO­LO-1 Phase III, two tri­als that have drummed up plen­ty of in­ter­est at the an­nu­al on­col­o­gy meet­up across the pond.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER